RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group
study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying
nodular bronchiectasis and documented MAC lung infection.